Non Hodgkin Lymphoma Clinical Trial
Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma
Summary
Phase 1 open label, multi-center, dose-escalation study for individuals with relapsed or refractory B-cell Non Hodgkin's Lymphoma.
Full Description
This study will evaluate the safety profile, pharmacokinetics, and efficacy of single-agent cosibelimab as well as the combination of Cosibelimab + Ublituximab + Bendamustin.
Eligibility Criteria
Key Inclusion Criteria:
Histologically confirmed relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).
Measurable disease and adequate organ function as specified in the protocol
Key Exclusion Criteria:
Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, or prior therapy with bendamustine.
Subjects receiving cancer therapy or investigational drug within 21 days of Cycle 1 Day 1.
Prior autologous stem cell transplant within 3 months
Active Hepatitis B or Hepatitis C
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 9 Locations for this study
Huntsville Alabama, 35805, United States
Tucson Arizona, 85711, United States
Fayetteville Arkansas, 72703, United States
Peoria Illinois, 61615, United States
Fort Wayne Indiana, 46804, United States
Fairway Kansas, 64154, United States
Louisville Kentucky, 40207, United States
Charlotte North Carolina, 28262, United States
Seattle Washington, 98108, United States
How clear is this clinincal trial information?
